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ABSTRACT 
The author presents a case of a loss of taste in two patients induced by methotrexate during the treatment of 
psoriatic erythrodermia. The loss of taste was confirmed by laboratory examinations in the Department of 
Physiology, Prof. P. Stoyanov, Varna University of Medicine. It is concluded that the loss of taste may be an 
adverse effect of methotrexate with temporary duration.
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INTRODUCTION
Methotrexate is an antimitotic drug that acts by competition 
with dihydrofolate reductase in the DNA synthesis (2). It 
exerts anti-inflammatory and anti-arthritic effects by de­
creasing the proliferation of lymphocytes and changing the 
polymorphonuclear chemotaxis (5). It acts as an anti-cancer 
drug in higher doses and as an anti-rheumatoid agent in 
lower doses (3). One study showed that methotrexate dam­
ages the epidermis by decreasing the proliferation of 
kératinocytes (4).
Adverse reactions associated with methotrexate treatment 
were reported in numerous studies Table. 1 (6). The adverse 
effects of methotrexate are commonly seen during 
anti-cancer chemotherapies (6). However, we did not find 
any studies about taste loss induced by methotrexate during 
the treatment of psoriatic erythrodermia.
MATERIAL AND M ETHODS CASE  
REPORT
Two male patients aged 82 and 56 years were diagnosed 
with psoriatic eiythrodermia. They were in good physical 
condition. They complained of itching on whole body. 
Dermatologie examination showed diffusely spread ery­
thema and desquamation. We treated both o f them with 
methotrexate orally (25mg weekly) and locally with emol­
lients in the Clinic of Dermatology and Venereology. After 
two months, dermatological status became normal, but they 
complained of taste loss and, subsequently, of low appetite 
and weight loss. Methotrexate was suspected, and this ther­
apy was stopped.
We proved that these complaints were not subjective by 
laboratory examinations. We investigated the limen of tasty 
sensitivity to basic types of taste ( 1 ). We established a lower
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taste sensitivity for salt and sour. The sensitivity to sweet 
and bitter was not changed.
RESULTS AND DISCUSSION
The most frequent reactions to methotrexate treatment are 
ulcerations of the oral mucosa, burning sensation of the 
skin, photosensitivity, acral erythema, erythema 
multiforme, urticaria, and vasculitis (6). Frequent risk fac-
Table 1. Methotrexate oral adverse effects
More frequent Less frequent Rare or very rare
appetite loss acne agranulocytosis
azotemia arachnoiditis, chemical alveolitis



















tors for toxicity were renal failure, infection, and old age. 
The loss of taste in our case is a reaction to methotrexate 
treatment because the patients do not take any other medi­
cations. Although one of them is not young, they were both 
in good physical condition and no other risk factors were 
noted. We proved that the complaints were not subjective. 
Dmg-induced taste loss is an embarrassing adverse effect 
but it ceases rapidly after removal of the responsible drug. 
In this case, taste loss restores after cessation of 
methotrexate therapy.
In summary, there are many toxic and adverse effects of 
methotrexate. Some of them may be eliminated with addi­
tional treatment; other ones should be prevented by 
premedication. Most of them are recurrent. To our knowl­
edge, this is die first case where a taste loss was induced by 
methotrexate and was described as possible adverse effect 
of this drug.
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